Optec: A Phase 2 Study to Evaluate Outpatient Administration of Teclistamab, a BCMA-Targeting Bispecific Antibody, in Patients with Multiple Myeloma

被引：3
|
作者：
Rifkin, Robert M. [1 ]
Sharman, Jeff P. [2 ]
Fowler, Jessica [3 ]
Lin, Thomas S. [3 ]
Thomson, Brian [4 ]
Berdeja, Jesus G. [5 ]
机构：
[1] US Oncol Res, Rocky Mt Canc Ctr, Denver, CO USA
[2] US Oncol Res, Willamette Valley Canc Inst & Res Ctr, Eugene, OR USA
[3] Johnson & Johnson Innovat Med, Horsham, PA USA
[4] Janssen Pharmaceut, Horsham, PA USA
[5] Sarah Cannon Res Inst, Nashville, TN USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185257
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] OPTec: A phase 2 study to evaluate outpatient (OP) step-up administration of teclistamab (Tec), a BCMA-targeting bispecific antibody, in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
    Rifkin, Robert M.
    Schade, Henning Helmut
    Simmons, Gary
    Yasenchak, Christopher A.
    Fowler, Jessica
    Lin, Thomas S.
    Thomson, Brian
    Xu, Weiming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Optec: A Phase 2 Study to Evaluate Outpatient Step-up Administration of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results
    Rifkin, Robert
    Schade, Henning
    Simmons, Gary
    Yasenchak, Christopher
    Fowler, Jessica
    Lin, Thomas S.
    Kang, Lijuan
    Xu, Weiming
    BLOOD, 2024, 144 : 4753 - 4754
  • [3] BCMA-targeting Bispecific Antibody That Simultaneously Stimulates NKG2D-enhanced Efficacy Against Multiple Myeloma
    Wang, Yang
    Li, Hui
    Xu, Wei
    Pan, Mingzhu
    Qiao, Chun
    Cai, Jialing
    Xu, Jingjing
    Wang, Min
    Zhang, Juan
    JOURNAL OF IMMUNOTHERAPY, 2020, 43 (06) : 175 - 188
  • [4] Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to BCMA-targeting bispecific antibody treatment
    San-Miguel, Jesus
    Mateos, Maria-Victoria
    Cohen, Yael C.
    Rodriguez-Otero, Paula
    Paiva, Bruno
    van de Donk, Niels W. C. J.
    Martin, Thomas
    Abu-Zaid, Mohammad
    Corsale, Christina
    Schecter, Jordan M.
    De Braganca, Kevin C.
    Varsos, Helen
    Deraedt, William
    Wang, Liwei
    Roccia, Tito
    Li, Claire
    Mistry, Pankaj
    Xu, Xiaoying
    Zudaire, Enrique
    Akram, Muhammad
    Nesheiwat, Tonia
    Pacaud, Lida
    Avivi, Irit
    Cohen, Adam D.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S35 - S36
  • [5] Characterization of Anthropometric Changes in Patients with Relapsed/Refractory Myeloma Treated with BCMA Bispecific Antibody Teclistamab
    Nader, Setarah Mohammad
    Jines, Tyler
    Collier, Christopher
    Zimmers, Teresa
    Abonour, Rafat
    Farag, Sherif
    Abu Zaid, Mohammad
    Lee, Kelvin P.
    Suvannasankha, Attaya
    BLOOD, 2023, 142
  • [6] Population pharmacokinetics of belantamab mafodotin, a BCMA-targeting agent in patients with relapsed/refractory multiple myeloma
    Rathi, Chetan
    Collins, Jon
    Struemper, Herbert
    Opalinska, Joanna
    Jewell, Roxanne C.
    Ferron-Brady, Geraldine
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 851 - 863
  • [7] Cilta-cel, a BCMA-targeting CAR-T therapy for patients with multiple myeloma
    Jagannath, Sundar
    Jackson, Carolyn C.
    Schecter, Jordan M.
    Lendvai, Nikoletta
    Sun, Huabin
    Akram, Muhammad
    Patel, Nitin
    Martin, Thomas G.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (05) : 339 - 350
  • [8] A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma
    Wang, Di
    Wang, Jue
    Hu, Guang
    Wang, Wen
    Xiao, Yi
    Cai, Haodong
    Jiang, Lijun
    Meng, Li
    Yang, Yongkun
    Zhou, Xiaoxi
    Hong, Zhenya
    Yao, Zheng
    Xiao, Min
    Chen, Liting
    Mao, Xia
    Zhu, Li
    Wang, Jin
    Qiu, Lugui
    Li, Chunrui
    Zhou, Jianfeng
    BLOOD, 2021, 137 (21) : 2890 - 2901
  • [9] Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/ Refractory Multiple Myeloma
    Chen, Wenming
    Fu, Chengcheng
    Fang, Baijun
    Liang, Aibin
    Xia, Zhongjun
    He, Yanjuan
    Lu, Jin
    Liu, Hui
    Hou, Ming
    Cai, Zhen
    Yang, Wei
    Hao, Siguo
    Jiang, Songfu
    Jing, Hongmei
    Liu, Jing
    Du, Xin
    Fu, Rong
    Mei, Heng
    Zhu, Zunmin
    Yang, Yanli
    Liu, Hong
    Yuan, Daijing
    Zhao, Hongxia
    Xiao, Jun
    Wang, Wei
    Wang, Huamao
    Li, Zonghai
    BLOOD, 2022, 140 : 4564 - 4565
  • [10] Exploring T cell subsets as predictors of response to BCMA targeting bispecific antibody therapy in multiple myeloma
    Shrestha, Asis
    Thostenson, Jeff
    Patel, Tanvi
    Bachu, Ramya
    Naqvi, Syed
    Trikannad, Anup Kumar
    Cheema, Hira Imad
    Shrivastava, Trilok
    Thanendrarajan, Sharmilan
    Al Hadidi, Samer
    Zangari, Maurizio
    van Rhee, Frits
    Schinke, Carolina D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345